Abstract 1008P
Background
TACE is the first choice for patients (pts) with intermediate-stage HCC. Numerous studies have demonstrated the limited survival benefit of TACE alone in pts with stage BCLC B, particularly in tumor beyond up-to-seven criteria. Single immunotherapy agent showed a certain effect for unresectable HCC pts, but still with unsatisfactory. This study was designed to explore the efficacy and safety of sintilimab plus cTACE for HCC with stage BCLC B (or stage CNLC IIa-IIb) beyond up-to-seven criteria.
Methods
This is a single-arm, phase II study(NCT04842565). Eligible HCC pts were treated cTACE and sintilimab (200mg, IV, Q3W). The first sintilimab dose was given after the first cTACE, and then every 3 weeks. The primary objectives were safety and progression-free survival (PFS). Secondary objectives included ORR assessed by both RECIST v1.1 and mRECIST v1.1, overall survival (OS), and disease control rate (DCR).
Results
From Oct 2020 to Feb 2023, 20 pts were enrolled with a median age of 62 years. All pts were BCLC stage B, and 45.0% (9/20) were CNLC IIa stage, 55.0% (11/20) were IIb stage. At median follow-up duration of 9.0 months, the ORR was 30.0%(95% CI: 14.6%-51.9%) per RECIST, and 60% (95%CI: 38.7%-78.1%) per mRECIST. The DCR was 95.0% (95% CI: 76.4%-99.1%) per both RECIST and mRECIST. Median PFS(by both RECIST and mRECIST) was 7.95 months (95% CI: 2.7-NA), and the median OS was not reached. Four pts converted to curative surgical resection. The optimal cut-off value of PLR(platelet-to-lymphocyte ratio) predicted tumor shrinkage was 100. Low PLR were associated with more tumor shrinkage. The most common TRAEs were hypothyroidism (37.5%), elevated aspartate aminotransferase (10.0%), rash(5.0%). Only one patient experienced grade 3 TRAE(myocarditis) and no treatment-related deaths were reported.
Conclusions
Combination of Sintilimab and cTACE showed promising antitumor activity and manageable toxicity in pts with HCC with BCLC stage B (CNLC stage IIa-IIb) beyond up-to-seven criteria. The PLR is promising predictor for tumor shrinkage in HCC. These strategy should be validated in a large randomized controlled trial.
Clinical trial identification
NCT04842565.
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan hospital affiliated to Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18